French Healthcare GroupSanofiIt has agreed to buy its American counterpart Bioverativ for 11.6 billion US dollars. Sanofi said the deal will boost the company's profits and strengthen the company's business in the field of rare disease treatment.
Sanofi agreed to buy all of Bioverativ's outstanding shares in cash at $105 per share, at a 64% premium over the latter's closing price on January 19, 2018. (End)